Halozyme Therapeutics (HALO) News Today $57.75 +0.31 (+0.54%) Closing price 02/21/2025 04:00 PM EasternExtended Trading$57.08 -0.67 (-1.17%) As of 02/21/2025 06:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period Benchmark Reaffirms "Buy" Rating for Halozyme Therapeutics (NASDAQ:HALO)Benchmark restated a "buy" rating and issued a $75.00 price objective on shares of Halozyme Therapeutics in a research report on Thursday.February 21 at 9:41 AM | marketbeat.comHussman Strategic Advisors Inc. Acquires 31,500 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)Hussman Strategic Advisors Inc. boosted its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 75.0% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 73,500 shares of the biopharmaceutical cFebruary 21 at 6:37 AM | marketbeat.comMeitav Investment House Ltd. Lowers Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO)Meitav Investment House Ltd. reduced its stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 37.9% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 39,116 shares of the biopharmaFebruary 21 at 6:09 AM | marketbeat.comHalozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Sold by Handelsbanken Fonder ABHandelsbanken Fonder AB lessened its stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 73.8% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 516,469 shares of the biopharmaceutical company'sFebruary 21 at 4:54 AM | marketbeat.comRhumbline Advisers Buys 5,833 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)Rhumbline Advisers lifted its stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 1.4% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 410,508 shares of the biophFebruary 21 at 3:32 AM | marketbeat.comVontobel Holding Ltd. Acquires Shares of 7,895 Halozyme Therapeutics, Inc. (NASDAQ:HALO)Vontobel Holding Ltd. purchased a new stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 7,895 shares of the biopharmaceuticaFebruary 21 at 3:23 AM | marketbeat.comAssessing Halozyme Therapeutics: Insights From 9 Financial AnalystsFebruary 20 at 4:22 PM | benzinga.comHalozyme price target raised to $60 from $57 at Wells FargoFebruary 20 at 11:20 AM | markets.businessinsider.comHalozyme Therapeutics Full Year 2024 Earnings: Beats ExpectationsFebruary 20 at 11:20 AM | finance.yahoo.comHC Wainwright Forecasts Strong Price Appreciation for Halozyme Therapeutics (NASDAQ:HALO) StockHC Wainwright boosted their price objective on shares of Halozyme Therapeutics from $70.00 to $72.00 and gave the company a "buy" rating in a research report on Wednesday.February 20 at 8:05 AM | marketbeat.comHalozyme Therapeutics (NASDAQ:HALO) Releases Quarterly Earnings Results, Beats Expectations By $0.02 EPSHalozyme Therapeutics (NASDAQ:HALO - Get Free Report) posted its earnings results on Tuesday. The biopharmaceutical company reported $1.19 earnings per share for the quarter, topping analysts' consensus estimates of $1.17 by $0.02. Halozyme Therapeutics had a return on equity of 179.82% and a net margin of 41.43%.February 19 at 8:44 PM | marketbeat.comHalozyme Therapeutics (NASDAQ:HALO) Issues Quarterly Earnings Results, Beats Estimates By $0.02 EPSHalozyme Therapeutics (NASDAQ:HALO - Get Free Report) issued its quarterly earnings data on Tuesday. The biopharmaceutical company reported $1.19 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.17 by $0.02. Halozyme Therapeutics had a return on equity of 179.82% and a net margin of 41.43%.February 19 at 8:43 PM | marketbeat.comHalozyme Therapeutics: Record Earnings and Future GrowthFebruary 19 at 7:36 PM | tipranks.comHalozyme Therapeutics Inc (HALO) Reports Record Revenue for 2024February 19 at 5:08 PM | gurufocus.comQ4 2024 Halozyme Therapeutics Inc Earnings CallFebruary 19 at 9:35 AM | finance.yahoo.comHalozyme price target raised to $72 from $70 at H.C. WainwrightFebruary 19 at 9:35 AM | markets.businessinsider.comHalozyme price target raised to $78 from $73 at Citizens JMPFebruary 19 at 9:35 AM | markets.businessinsider.comHalozyme Therapeutics, Inc. (NASDAQ:HALO) Q4 2024 Earnings Call TranscriptFebruary 19 at 9:35 AM | msn.comConvergence Investment Partners LLC Grows Stock Holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO)Convergence Investment Partners LLC boosted its position in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 25.9% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 34,713 shares of the biopharmFebruary 19 at 6:19 AM | marketbeat.comKornitzer Capital Management Inc. KS Has $10.19 Million Stock Holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO)Kornitzer Capital Management Inc. KS trimmed its holdings in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 51.8% in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 213,199 shares of the biopharmaceutical cFebruary 19 at 5:06 AM | marketbeat.comHalozyme Therapeutics Inc (HALO) Q4 2024 Earnings Call Highlights: Record Revenue and Strong ...February 19 at 2:24 AM | gurufocus.comQ4 2024 Halozyme Therapeutics Inc Earnings Call TranscriptFebruary 19 at 12:17 AM | gurufocus.comHalozyme Therapeutics Achieves Record Revenue in 2024February 18, 2025 | tipranks.comHalozyme Therapeutics Inc (HALO) Q4 Earnings: EPS of $1. ...February 18, 2025 | gurufocus.comHalozyme Therapeutics, Inc. (HALO) Q4 2024 Earnings Call TranscriptFebruary 18, 2025 | seekingalpha.comHalozyme reports Q4 non-GAAP EPS $1.26, consensus $1.16February 18, 2025 | markets.businessinsider.comHalozyme Therapeutics, Inc. 2024 Q4 - Results - Earnings Call PresentationFebruary 18, 2025 | seekingalpha.comHALOZYME REPORTS FULL YEAR 2024 RECORD REVENUE OF $1.015 BILLION AND EXCEEDS ITS FINANCIAL GUIDANCE FOR ROYALTY REVENUE, ADJUSTED EBITDA AND NON-GAAP DILUTED EPSFebruary 18, 2025 | prnewswire.comHalozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Sold by Kestra Private Wealth Services LLCKestra Private Wealth Services LLC trimmed its stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 49.6% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 9,314 shares of the biopharmaceutical company's stockFebruary 17, 2025 | marketbeat.comHalozyme Therapeutics (HALO) to Release Quarterly Earnings on TuesdayFebruary 17, 2025 | americanbankingnews.comCongress Asset Management Co. Sells 473,843 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)Congress Asset Management Co. decreased its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 19.5% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,959,736 shares of the biopharmaceutical company'sFebruary 16, 2025 | marketbeat.comHalozyme assumed with an Overweight at Morgan StanleyFebruary 15, 2025 | markets.businessinsider.comHalozyme director Connie Matsui to exit boardFebruary 14, 2025 | msn.comHere's How Much You'd Have If You Invested $1000 in Halozyme Therapeutics a Decade AgoFebruary 12, 2025 | msn.comHalozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Purchased by Davidson Capital Management Inc.Davidson Capital Management Inc. boosted its stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 111.2% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 56,639 shares of the biopharmaceutiFebruary 12, 2025 | marketbeat.comHalozyme Therapeutics, Inc. (HALO): A Cheap Biotech Stock to Invest In NowFebruary 12, 2025 | insidermonkey.comShaker Investments LLC OH Grows Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO)Shaker Investments LLC OH lifted its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 12.3% in the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 75,326 shares of the biopharmaceutical company's stock after purchasing an additionFebruary 11, 2025 | marketbeat.comHalozyme Therapeutics (HALO) Projected to Post Quarterly Earnings on TuesdayHalozyme Therapeutics (NASDAQ:HALO) will be releasing earnings after the market closes on Tuesday, February 18, Financial Modeling Prep reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=467381)February 11, 2025 | marketbeat.comState of Alaska Department of Revenue Buys 31,670 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)State of Alaska Department of Revenue grew its stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 213.4% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 46,508 shares of the biopharmaceuticalFebruary 11, 2025 | marketbeat.comWCM Investment Management LLC Cuts Stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO)WCM Investment Management LLC cut its stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 5.1% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 284,622 shares of the biopharmaceutical coFebruary 10, 2025 | marketbeat.comZacks Research Issues Pessimistic Outlook for HALO EarningsHalozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) - Equities researchers at Zacks Research lowered their Q1 2025 earnings per share estimates for shares of Halozyme Therapeutics in a research report issued on Wednesday, February 5th. Zacks Research analyst R. Department now forecasts that tFebruary 10, 2025 | marketbeat.comStephens Investment Management Group LLC Reduces Holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO)Stephens Investment Management Group LLC decreased its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 0.9% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 1,346,957 shares of the biopharmaceutical company'February 9, 2025 | marketbeat.comFinancial Advocates Investment Management Buys Shares of 9,989 Halozyme Therapeutics, Inc. (NASDAQ:HALO)Financial Advocates Investment Management bought a new stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 9,989 shares of the biopharmaceuticalFebruary 9, 2025 | marketbeat.com128,670 Shares in Halozyme Therapeutics, Inc. (NASDAQ:HALO) Purchased by abrdn plcabrdn plc purchased a new stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 128,670 shares of the biopharmaceutical company's stock, valued at approximFebruary 9, 2025 | marketbeat.comAdvisors Preferred LLC Makes New $2.02 Million Investment in Halozyme Therapeutics, Inc. (NASDAQ:HALO)Advisors Preferred LLC acquired a new stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 42,162 shares of the biopharmaceutical company'February 8, 2025 | marketbeat.comWhat is Zacks Research's Forecast for HALO Q2 Earnings?Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) - Zacks Research decreased their Q2 2025 earnings per share estimates for shares of Halozyme Therapeutics in a report released on Wednesday, February 5th. Zacks Research analyst R. Department now forecasts that the biopharmaceutical companyFebruary 7, 2025 | marketbeat.comJennison Associates LLC Takes Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO)Jennison Associates LLC bought a new stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 15,291 shares of the biopharmaceutical company'sFebruary 7, 2025 | marketbeat.comHalozyme Therapeutics, Inc. (NASDAQ:HALO) Given Average Rating of "Moderate Buy" by BrokeragesShares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Get Free Report) have been assigned an average rating of "Moderate Buy" from the ten analysts that are currently covering the firm, MarketBeat.com reports. Four equities research analysts have rated the stock with a hold rating and six have assigFebruary 7, 2025 | marketbeat.comHalozyme Stock Climbs Back After 2024 Sneak Peak As Earnings LoomFebruary 6, 2025 | msn.comInsider Sell: Jeffrey Henderson Sells 5,000 Shares of Halozyme Therapeutics Inc (HALO)February 5, 2025 | gurufocus.com Get Halozyme Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for HALO and its competitors with MarketBeat's FREE daily newsletter. Email Address HALO Media Mentions By Week HALO Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. HALO News Sentiment▼0.740.60▲Average Medical News Sentiment HALO News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. HALO Articles This Week▼369▲HALO Articles Average Week Get Halozyme Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for HALO and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies BIIB News Today UTHR News Today INCY News Today BMRN News Today NBIX News Today EXEL News Today EXAS News Today RGEN News Today MDGL News Today ALKS News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:HALO) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementGrab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which ...Crypto 101 Media | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now...Colonial Metals | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredWhat is this southern state hiding?The financial press had a field day this week after President Donald Trump and Department of Government Effici...Stansberry Research | SponsoredElon Takes Aim at Social SecurityElon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Halozyme Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Halozyme Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free HALO Stock Alerts